Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit

Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit

BACKGROUND: Patient support programs (PSPs) improve medication-taking behavior in the first 12 months of treatment for patients with immune-mediated diseases, but it is unknown if these benefits are sustained. As immune-mediated diseases continue to increase in prevalence and economic burden, unders...

Full description

Bibliographic Details
Main Authors: Brixner, D. (Author), Davis, M. (Author), Fendrick, A.M (Author), Liu, H. (Author), Mease, P. (Author), Mittal, M. (Author), Rubin, D.T (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
adalimumab
adult
ankylosing spondylitis
antirheumatic agent
Antirheumatic Agents
Article
cohort analysis
controlled study
Crohn disease
data availability
dermatology
eligibility criteria
female
Female
follow up
gastroenterology
hazard ratio
health care cost
Health Care Costs
health program
hospital care
hospitalization
Hospitalization
human
Humans
ICD-9
identifiable information
immunopathology
Kaplan Meier method
long term care
longitudinal study
low risk patient
major clinical study
male
Male
Medication Adherence
medication compliance
middle aged
Middle Aged
prevalence
proportional hazards model
Proportional Hazards Models
psoriasis
psoriatic arthritis
Retrospective Studies
retrospective study
rheumatoid arthritis
rheumatology
social participation
social support
Social Support
suppurative hidradenitis
treatment duration
ulcerative colitis
uveitis
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items